Rhabdomyolysis during therapy with daptomycin.
The use of daptomycin has been associated with an elevation in creatine phosphokinase level, with a reported incidence of 2.8% in phase III clinical trials. Published case reports have documented the presence of myopathy in patients who received daptomycin; however, there have been no previously reported cases of rhabdomyolysis in animals or humans to date. We describe a case of rhabdomyolysis during therapy with daptomycin.
Papadopoulos
Stella
S
Department of Pharmacy, University of Kentucky Chandler Medical Center, Lexington, Kentucky 40536, USA. spapa2@email.uky.edu
Ball
Amanda M
AM
Liewer
Susanne E
SE
Martin
Craig A
CA
Winstead
P Shane
PS
Murphy
Brian S
BS
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017576:Daptomycin / Q000009:adverse effects* / Q000627:therapeutic use; D016984:Enterococcus faecium; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D017576:Daptomycin